AMSBIO has expanded its catalogue of primary and progenitor cell types and media with a new range of human endothelial progenitor cells (EPC).
Human endothelial progenitor cells are a primitive cell type. They are bone marrow derived cells with properties similar to embryonic angioblasts.
Progenitor cells migrate into the blood stream and are able to differentiate into a variety of mature vascular endothelial cell types. EPC play an important role in both angiogenesis and vasculogenesis.
Compared with specific mature types of endothelial cells such as HMVECs and HUVECs, human EPC are more suitable for cell-based screening of anti-cancer drugs. Endothelial progenitor cells also have an impact on ageing and smoking-related diseases, thereby offering beneficial research and drug discovery use in these areas.
AMSBIO offers various specific sub-types of human EPC including vein, microvascular and aortic. The gene expression pattern of AMSBIO endothelial progenitor cells is more similar to that of endothelial cells from tumours and therefore they offer the advantage of specifically migrating to human tumours.
Endothelial progenitor cells from AMSBIO are isolated from human samples using proprietary technology. These EPC are delivered at the 4th passage, either as cryopreserved or proliferating cells in culture flasks. Each cryovial contains >5 x 100,000 cells in 1 ml volume 24-, 96-, or 384-well formats, ready for screening, are also available upon request.
